EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Karim Fizazi, Josep M Piulats, M Neil Reaume, Peter Ostler, Ray McDermott, Joel R Gingerich, Elias Pintus, Srikala S Sridhar, Richard M Bambury, Urban Emmenegger, Henriette Lindberg, David Morris und 17 weitere

New England Journal of Medicine · 23.02.2023 · 388 (8) · 719-732

DOI: 10.1056/nejmoa2214676 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 23.02.2023. Verfasst von Karim Fizazi und 28 weiteren Autor:innen. Beteiligte Einrichtung: From Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); Institut Català d'Oncologia-Bellvitge Institute for Biomedical Rese…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents. Die Arbeit wurde bisher 445-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Clovis Oncology, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAntineoplastic AgentsHumansMaleAntineoplastic Combined Chemotherapy ProtocolsIndolesProgression-Free SurvivalPoly(ADP-ribose) Polymerase InhibitorsAndrogen AntagonistsDocetaxelDisease ProgressionGenes, BRCA1Genes, BRCA2AndrostenesBenzamidesNitrilesPhenylthiohydantoinAtaxia Telangiectasia Mutated Proteins

Substanzen

IndolesPoly(ADP-ribose) Polymerase InhibitorsAndrogen AntagonistsAntineoplastic AgentsDocetaxelrucaparibabirateroneAndrostenesenzalutamideBenzamides

Autor:innen und Institutionen

  • From Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); Institut Català d'Oncologia-Bellvitge Institute for Biomedical Research -CiberOnc, Barcelona (J.M.P.), and the Medical Oncology Intercent…

ORCID-Profile: Simon P Watkins, Alan H Bryce

Förderung

  • NCI NIH HHS
  • Clovis Oncology
  • National Cancer Institute

Zitieren

APA

Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., Lindberg, H., Morris, D., Nolè, F., Staffurth, J., Redfern, C., Sáez, M. I., Abida, W., Daugaard, G., Heidenreich, A., …, & TRITON3 Investigators (2023). Rucaparib or Physician’s Choice in Metastatic Prostate Cancer. New England Journal of Medicine, 388(8), 719-732. https://doi.org/10.1056/nejmoa2214676

Vancouver

Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer. New England Journal of Medicine. 2023;388(8):719-732. doi:10.1056/nejmoa2214676

BibTeX
@article{Fizazi2023,
  author = {Fizazi, Karim and Piulats, Josep M and Reaume, M Neil and Ostler, Peter and McDermott, Ray and Gingerich, Joel R and Pintus, Elias and Sridhar, Srikala S and Bambury, Richard M and Emmenegger, Urban and Lindberg, Henriette and Morris, David and Nolè, Franco and Staffurth, John and Redfern, Charles and Sáez, María I and Abida, Wassim and Daugaard, Gedske and Heidenreich, Axel and Krieger, Laurence and Sautois, Brieuc and Loehr, Andrea and Despain, Darrin and Heyes, Catherine A and Watkins, Simon P and Chowdhury, Simon and Ryan, Charles J and Bryce, Alan H and TRITON3 Investigators, TRITON3 Investigators},
  title = {Rucaparib or Physician’s Choice in Metastatic Prostate Cancer},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {8},
  pages = {719--732},
  doi = {10.1056/nejmoa2214676}
}
Kostenlos starten →